Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

• DOI: 10.6004/jnccn.2020.0021
• Publication Date: 2020-05-07T10:20:53Z
• Authors: Ayman Saad; Marcos de Lima; Sarah Anand; Vijaya Raj Bhatt; Ryan Bookout; George Chen; Daniel Couriel; Antonio Di Stasi; Areej El-Jawahri; Sergio Giralt; Jonathan Gutman; Vincent Ho; Mitchell Horwitz; Joe Hsu; Mark Juckett; Mohamed Kharfan D...; Alison W. Loren; ; Javier Meade; Marco Mielcarek; Jonathan Moreira; Ryotaro Nakamura; Yago Nieto; Julianna Roddy; Gowri Satyanarayana; Mark Schroeder; Carlyn Rose Tan; Dimitrios Tzachanis; Jennifer L. Burns; Lenora A. Pluchino
• Keywords: Male; 03 medical and health sciences; 0302 clinical medicine; Hematopoietic Stem Cell Transplantation; Humans; Female; Guidelines as Topic; 3. Good health

Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor cells into patients with hematologic disorders goal re-establishing normal and immune function. HCT is classified as autologous or allogeneic based on origin cells. Autologous uses patient’s own while from a human leukocyte antigen-compatible donor. Allogeneic potentially curative treatment option for certain types malignancies, primarily used to support undergoing high-dose chemotherapy. Advances in methods supportive care recent decades have led improved survival after HCT; however, disease relapse posttransplant complications still commonly occur both recipients. recipients may also develop acute and/or chronic graft-versus-host (GVHD), which results immune-mediated cellular injury several organs. The NCCN Guidelines Cell Transplantation focus recommendations pretransplant recipient evaluation management GVHD adult malignant disease.